Share This Page
Drug Price Trends for AMRIX ER
✉ Email this page to a colleague
Average Pharmacy Cost for AMRIX ER
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| AMRIX ER 15 MG CAPSULE | 63459-0700-60 | 66.23256 | EACH | 2026-01-01 |
| AMRIX ER 30 MG CAPSULE | 63459-0701-60 | 66.56709 | EACH | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for AMRIX ER
What is the current market landscape for AMRIX ER?
AMRIX ER (Cyclobenzaprine extended-release) is a muscle relaxant indicated for the relief of muscle spasms associated with acute musculoskeletal conditions. It is marketed as an extended-release formulation, intended for once-daily dosing, compared to immediate-release versions taken multiple times daily.
The drug has been approved by the FDA, with approval date in 2011. Its market penetration remains modest due to competition from generic alternatives and other musculature relaxants. The U.S. market is the primary revenue generator, with limited international sales.
Competitive landscape
AMRIX ER faces competition from:
- Generic cyclobenzaprine formulations (immediate-release)
- Other extended-release muscle relaxants, such as Flexeril XR (cyclobenzaprine), which was withdrawn from the U.S. market but remains available in some regions.
- Non-pharmacologic treatments like physical therapy and alternative therapies.
Market share is chiefly held by generics, which limit revenue potential for the branded product.
Market size and growth
The U.S. muscle relaxant market was valued at approximately USD 650 million in 2022. It is projected to grow at a compounded annual growth rate (CAGR) of around 4% through 2028, driven by aging populations and an increase in musculoskeletal injury incidence.
The segment specific to extended-release formulations is smaller but benefits from consumer preference for once-daily dosing and perceived improved compliance.
What are the key factors affecting AMRIX ER’s market performance?
- Pricing pressure from generics: Generic cyclobenzaprine costs approximately USD 10–15 per month, significantly lower than branded AMRIX ER, which is priced around USD 400–USD 500 monthly.
- Prescriber preferences: Physicians favor cost-effective generics unless there is clear clinical superiority.
- Patient adherence: Once-daily formulations attract increased adherence, possibly translating into improved outcomes and sustained market share.
- Regulatory developments: Any new approvals or patent litigations could influence market dynamics.
What are the price projections for AMRIX ER?
Current pricing context
- Brand name (AMRIX ER): Approximate retail price is USD 450–USD 500 per month based on pharmacy billing data.
- Generics: USD 10–USD 15 per month.
Short-term projections (next 2–3 years)
- Prices are likely to remain stable due to limited competition for the branded product.
- Market share could slightly decline if payors favor generics, but the branded product may maintain premium pricing based on its extended-release formulation.
Medium-term projections (3–5 years)
- If patent protections, exclusivity, or market strategies change, AMRIX ER could see price erosion.
- Market share is expected to shrink if generics dominate the therapy landscape.
- Anti-trust or patent litigation could influence pricing if generics are delayed or restricted.
Long-term outlook (5+ years)
- Likely decline in branded sales as generics become the standard of care.
- Pricing may decline to USD 200–USD 300 per month if brand rights are lost or if new formulations emerge.
- Alternatively, the company could pursue line extensions or combination therapies to preserve market positioning.
What strategic considerations exist?
- Patents protecting AMRIX ER expiration date in 2027 could influence pricing strategies.
- Investment in direct-to-consumer marketing might sustain premium pricing slightly longer.
- Differentiation through clinical benefits or improved adherence may impact future market share and pricing.
Summary table
| Factor | Current status | Impact on Price & Market Share |
|---|---|---|
| Price (monthly) | USD 450–USD 500 | Maintains high price but limited market penetration |
| Generic pricing | USD 10–USD 15 | Pressures branded pricing |
| Market size (2022) | USD 650 million | Steady growth, slight market share shift to generics |
| Growth rate (2022–2028) | 4% CAGR | Expanding total market, declining branded share |
| Patent expiration | 2027 | Potential for price erosion or generic competition |
Key Takeaways
- AMRIX ER's current pricing remains premium due to extended-release benefits but faces competition from low-cost generics.
- Market growth continues modestly; branded revenue will decline if patent protections lapse without new extensions.
- Price projections indicate stability in short term, potential decline over 3-5 years due to generic competition.
- Strategies to extend exclusivity or develop new formulations could sustain higher prices longer.
- Cost sensitivity among payors and physicians favors generics, constraining branded product pricing.
FAQs
1. How does AMRIX ER compare to immediate-release cyclobenzaprine?
AMRIX ER offers once-daily dosing with potentially better adherence and fewer side effects, but at a significantly higher price point than immediate-release formulations.
2. What is the patent status for AMRIX ER?
The primary patent is set to expire in 2027, after which generic versions are expected to enter the market.
3. How does insurance impact pricing and access for AMRIX ER?
Insurance coverage favors generic drug use; high out-of-pocket costs reduce consumption of the branded product.
4. Are there emerging competitors or alternative therapies?
Non-pharmacologic options like physical therapy are becoming more prominent, but no direct pharmaceutical substitutes are expected to challenge AMRIX ER in the near term.
5. What opportunities exist for premium pricing or market expansion?
Developing new formulations, combination therapies, or demonstrating clinical benefits over generics could justify premium pricing and extend market presence.
References
[1] IQVIA. (2023). Muscle Relaxants Market Data.
[2] U.S. Food and Drug Administration (FDA). (2011). Approval Letter for AMRIX.
[3] GoodRx. (2023). Cyclobenzaprine Pricing Overview.
[4] MarketWatch. (2023). Pharmaceutical Industry Trends.
[5] Centers for Disease Control and Prevention (CDC). (2022). Musculoskeletal Injury Statistics.
More… ↓
